ATE184201T1 - Durch enzyme und licht aktivierbares arzneimittelabgabesystem zur gleichzeitigen abgabe von arzneimitteln - Google Patents

Durch enzyme und licht aktivierbares arzneimittelabgabesystem zur gleichzeitigen abgabe von arzneimitteln

Info

Publication number
ATE184201T1
ATE184201T1 AT93904633T AT93904633T ATE184201T1 AT E184201 T1 ATE184201 T1 AT E184201T1 AT 93904633 T AT93904633 T AT 93904633T AT 93904633 T AT93904633 T AT 93904633T AT E184201 T1 ATE184201 T1 AT E184201T1
Authority
AT
Austria
Prior art keywords
drug
attached
copolymeric
carrier
anticancer
Prior art date
Application number
AT93904633T
Other languages
English (en)
Inventor
Jindrich Kopecek
Nancy Krinick
Original Assignee
Univ Utah
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah filed Critical Univ Utah
Application granted granted Critical
Publication of ATE184201T1 publication Critical patent/ATE184201T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/811—Peptides or proteins is immobilized on, or in, an inorganic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/816—Attached to the carrier via a bridging agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Processing Of Solid Wastes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT93904633T 1992-01-21 1993-01-21 Durch enzyme und licht aktivierbares arzneimittelabgabesystem zur gleichzeitigen abgabe von arzneimitteln ATE184201T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/822,924 US5258453A (en) 1992-01-21 1992-01-21 Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light

Publications (1)

Publication Number Publication Date
ATE184201T1 true ATE184201T1 (de) 1999-09-15

Family

ID=25237341

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93904633T ATE184201T1 (de) 1992-01-21 1993-01-21 Durch enzyme und licht aktivierbares arzneimittelabgabesystem zur gleichzeitigen abgabe von arzneimitteln

Country Status (14)

Country Link
US (1) US5258453A (de)
EP (1) EP0621880B1 (de)
JP (1) JPH08500327A (de)
KR (1) KR100217186B1 (de)
AT (1) ATE184201T1 (de)
AU (1) AU663167B2 (de)
CA (1) CA2128330A1 (de)
DE (1) DE69326322T2 (de)
DK (1) DK0621880T3 (de)
FI (1) FI943430A7 (de)
HU (1) HUT68082A (de)
PL (1) PL172184B1 (de)
RU (1) RU94038047A (de)
WO (1) WO1993014142A1 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5482719A (en) * 1992-10-30 1996-01-09 Guillet; James E. Drug delivery systems
US20040071637A1 (en) * 1993-04-27 2004-04-15 Elia James P. Method for repairing a damaged portion of a human organ
US5449720A (en) * 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
GB9320781D0 (en) * 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
JP3315782B2 (ja) 1993-11-09 2002-08-19 理化学研究所 光化学反応による血液中抗癌剤変換装置
US5444650A (en) * 1994-01-25 1995-08-22 Nippondenso Co., Ltd. Semiconductor programmable read only memory device
US5599831A (en) * 1994-05-27 1997-02-04 Poretz; Ronald D. Method of preparation of pharmaceutical compositions
NO180167C (no) * 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US6316007B1 (en) 1995-04-04 2001-11-13 Wound Healing Of Oklahoma Combined physical and immunotherapy for cancer
CA2215978A1 (en) * 1995-04-04 1996-10-10 Wound Healing Of Oklahoma Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant
US5776925A (en) * 1996-01-25 1998-07-07 Pharmacyclics, Inc. Methods for cancer chemosensitization
US6375930B2 (en) 1996-06-04 2002-04-23 Board Of Regents, The University Of Texas System Membrane incorporation of texaphyrins
US6493570B1 (en) 1998-11-02 2002-12-10 Photogen, Inc. Method for improved imaging and photodynamic therapy
WO1999002139A1 (en) * 1997-07-10 1999-01-21 Keith Baker Methods for universally distributing therapeutic agents to the brain
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
EP1011705A4 (de) * 1997-08-05 2000-09-20 Watson Pharmaceuticals Inc Konjugate, die auf den interleukin-2 rezeptor zielgerichtet sind
US8974363B2 (en) 1997-12-11 2015-03-10 Provectus Pharmatech, Inc. Topical medicaments and methods for photodynamic treatment of disease
EP2138191A1 (de) 1998-01-05 2009-12-30 University Of Washington Erhöhter Transport unter Benutzung membranzerstörender Stoffe
US6087952A (en) * 1998-03-06 2000-07-11 Mobile Information Systems, Inc. Remote mobile data suite and method
US6223071B1 (en) * 1998-05-01 2001-04-24 Dusa Pharmaceuticals Inc. Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light
US20030223978A1 (en) * 1998-05-22 2003-12-04 Nabi Ivan R. Conjugates of an AMF ligand and a cytotoxic molecule for use in cancer therapy
US8557298B2 (en) 1998-08-06 2013-10-15 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US6986740B2 (en) * 1998-11-02 2006-01-17 Xantech Pharmaceuticals, Inc. Ultrasound contrast using halogenated xanthenes
US6222093B1 (en) * 1998-12-28 2001-04-24 Rosetta Inpharmatics, Inc. Methods for determining therapeutic index from gene expression profiles
US20030114366A1 (en) * 1999-01-11 2003-06-19 Francis J. Martin Microfabricated particles and method for treating solid tumors
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
WO2001036002A1 (en) * 1999-11-17 2001-05-25 School Of Pharmacy, University Of London Conjugates of hpma copolymer and ellipticin
WO2001051092A2 (en) * 2000-01-07 2001-07-19 University Of Washington Enhanced transport of agents using membrane disruptive agents
US6455073B1 (en) 2000-07-10 2002-09-24 Enzrel, Inc. Covalent microparticle-drug conjugates for biological targeting
US6454790B1 (en) * 2000-07-21 2002-09-24 Ceramoptec Industries, Inc. Treatment for Barrett's syndrome
HU229805B1 (en) 2000-11-29 2014-07-28 Pci Biotech As Photochemical internalization for delivery of molecules into the cytosol
EP1343531A2 (de) * 2000-12-21 2003-09-17 McGILL UNIVERSITY Konjugate von antikörpern und antikrebsmitteln
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
EP1974752B1 (de) * 2001-04-30 2012-09-26 BioMarin Pharmaceutical Inc. Subzelluläres Targeting von therapeutischen Proteinen
US20040234497A1 (en) * 2001-05-04 2004-11-25 Yi Luo Hyaluronic acid containing bioconjugates:targeted delivery of anti-cancer drugs to cancer cells
WO2003017938A2 (en) * 2001-08-22 2003-03-06 Watson Pharmaceuticals, Inc. Conjugates targeted to target receptors
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
CA2822457C (en) 2001-12-14 2016-03-08 The University Of Wyoming Methods and compositions for controlled resease of drugs
US6846311B2 (en) * 2002-04-02 2005-01-25 Acueity, Inc. Method and apparatus for in VIVO treatment of mammary ducts by light induced fluorescence
CA2483696A1 (en) * 2002-05-06 2003-11-20 University Of Utah Research Foundation Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
AU2003282683A1 (en) * 2002-10-04 2004-05-04 Photokinetix Inc. Photokinetic delivery of biologically active substances using pulsed incoherent light
RU2256285C1 (ru) * 2003-10-14 2005-07-10 Закрытое акционерное общество "Электротекс" Способ плавного управления асинхронным электродвигателем с короткозамкнутым ротором
CA2553955C (en) * 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
EP1737428B1 (de) * 2004-03-31 2017-08-30 University of Utah Research Foundation Makromolekulare abgabesysteme für die nichtinvasive darstellung, untersuchung und behandlung von arthritis und anderen entzündlichen erkrankungen
US20070287680A1 (en) * 2004-05-10 2007-12-13 University Of Utah Research Foundation Combined Active and Passive Targeting of Biologically Active Agents
US20090209508A1 (en) * 2005-05-16 2009-08-20 Universite De Geneve Compounds for Photochemotherapy
US7465312B2 (en) 2006-05-02 2008-12-16 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
US20090326435A1 (en) * 2006-05-02 2009-12-31 Green Medical, Inc. Systems and methods for treating superficial venous malformations like varicose or spider veins
WO2007130465A2 (en) * 2006-05-02 2007-11-15 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
US9150626B2 (en) 2006-06-02 2015-10-06 President And Fellows Of Harvard College Protein surface remodeling
WO2007143209A2 (en) * 2006-06-02 2007-12-13 University Of Virginia Patent Foundation Luminescent diketonate polymers
GB0618524D0 (en) 2006-09-20 2006-11-01 Isis Innovation Multimeric particles
CA2669347A1 (en) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
ES2629853T3 (es) * 2008-05-07 2017-08-16 Biomarin Pharmaceutical Inc. Péptidos de dirección lisosómica y usos de los mismos
CN102264396A (zh) * 2008-10-07 2011-11-30 瑞沙恩医药公司 Hpma-多西他赛或吉西他滨缀合物及其用途
KR20100083632A (ko) * 2009-01-14 2010-07-22 울산대학교 산학협력단 표적 단백질 분해효소 감응형 항암제 전구체
US9221886B2 (en) * 2009-04-28 2015-12-29 President And Fellows Of Harvard College Supercharged proteins for cell penetration
EP2475376B1 (de) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulierungen für lysosomale enzyme
WO2011047051A2 (en) 2009-10-13 2011-04-21 Rexahn Pharmaceuticals, Inc. Polymeric systems for the delivery of anticancer agents
US8492339B2 (en) * 2009-10-26 2013-07-23 Empire Technology Development Llc Angiogenesis promoted by caged growth factors
JP5944836B2 (ja) 2010-03-08 2016-07-05 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 高分子薬物送達結合体ならびにその製造および使用方法
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
ES2853204T3 (es) 2010-05-25 2021-09-15 Syndevrx Inc Inhibidores de MetAP2 conjugado con polímero, y métodos terapéuticos de uso de los mismos
WO2012176023A1 (en) 2011-06-23 2012-12-27 Indian Institute Of Technology Kanpur Hydrogel scaffolds for tissue engineering
HUE032791T2 (en) * 2011-09-05 2017-11-28 Hiroshi Maeda Polymer-type fluorescent molecule probe
US11773188B2 (en) 2012-01-20 2023-10-03 Immunophotonics, Inc Chitosan-derived compositions
AU2013209716B2 (en) 2012-01-20 2017-04-27 Immunophotonics, Inc. Chitosan-derived compositions
MX386958B (es) 2013-04-10 2025-03-19 Syndevrx Inc Inhibidores de metionina aminopeptidasa-2 y métodos de tratamiento de la obesidad.
US20190002594A1 (en) 2014-07-16 2019-01-03 Immunophotonics, Inc. Chitosan-Derived Compositions
AU2016366306B2 (en) 2015-12-10 2021-02-25 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
WO2017123603A1 (en) 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
AU2017283653C1 (en) 2016-06-16 2022-05-05 Oncoselect Therapeutics, Llc Porphyrin compounds and compositions useful for treating cancer
JP7136807B2 (ja) 2017-04-17 2022-09-13 ザ・ユニバーシティ・オブ・シカゴ ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料
JP6894747B2 (ja) * 2017-04-19 2021-06-30 キヤノン株式会社 重合体
CN113453721B (zh) 2018-10-26 2025-09-16 辛德弗雷克斯公司 Metap2抑制剂的生物标志物及其应用
WO2021076865A1 (en) 2019-10-18 2021-04-22 University Of Utah Research Foundation Polymeric drug delivery conjugates and methods of making and using thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0103184B1 (de) * 1982-08-12 1990-01-17 Kanegafuchi Chemical Industry Co., Ltd. Aktivierung bioverträglicher Terpolymere mit biologischen Stoffen, deren anzubindende Komplemente pathologische Effektoren sind
GB8500209D0 (en) * 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
EP0213811A3 (de) * 1985-08-16 1987-09-09 Johnson Matthey, Inc., Bakteriozin-gerichtete Verbindungen zur Krebstherapie

Also Published As

Publication number Publication date
WO1993014142A1 (en) 1993-07-22
EP0621880A1 (de) 1994-11-02
FI943430A7 (fi) 1994-09-20
CA2128330A1 (en) 1993-07-22
DE69326322D1 (de) 1999-10-14
DE69326322T2 (de) 2000-02-17
JPH08500327A (ja) 1996-01-16
AU663167B2 (en) 1995-09-28
DK0621880T3 (da) 1999-12-20
KR100217186B1 (ko) 1999-09-01
PL172184B1 (pl) 1997-08-29
EP0621880A4 (de) 1995-04-19
HUT68082A (en) 1995-05-29
HU9402142D0 (en) 1994-09-28
EP0621880B1 (de) 1999-09-08
US5258453A (en) 1993-11-02
AU3593093A (en) 1993-08-03
FI943430A0 (fi) 1994-07-20
RU94038047A (ru) 1996-06-10

Similar Documents

Publication Publication Date Title
DE69326322D1 (de) Durch enzyme und licht aktivierbares arzneimittelabgabesystem zur gleichzeitigen abgabe von arzneimitteln
US20010044623A1 (en) Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue
HUT43948A (en) Emulsion compositions for dosing ionizable hydrophobic medical substances which are little soluble in water and process for preparing the same
DK1061900T4 (da) Dermale præparater
BR0109266A (pt) Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto
DE68918860D1 (de) Photoempfindliche mittel.
BRPI0416028B8 (pt) composto, conjugados do composto, composição farmacêutica e usos do conjugado
KR970705413A (ko) 암의 광역학요법용 새로운 로다민 유도체 및 백혈병의 시험관내 정화(novel rhodamine derivatives for photodynamic therapy of cancer and in vitro purging of the leukemias)
GEP20022804B (en) Erythropoietin Derivatives
CA2125189A1 (en) Pyropheophorbides and their use in photodynamic therapy
DK1137436T3 (da) Stimulering af T-celler mod selvantigener under anvendelse af CTLA-4-blokeringsmidler
ATE308545T1 (de) Chlorophyll- und bacteriochlorophyllester, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
WO1999024074A3 (en) Novel conjugates of opioids and endogenous carriers
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
WO2004027045A3 (en) Polymer-linker-drug conjugates for targeted drug delivery
IL115138A (en) Implantable polymer-containing molded articles for the administration of active substances to plants and processes for the preparation thereof
TR200001147T2 (tr) Kanser ve makular dejenerasyonun tedavisi için makrolidlerin kullanımı
EP0848948A4 (de) Lang wirksames mittel zur rektalen verabreichung
ES2376739T3 (es) Administración conjunta de un polisacárido con un agente quimioterapéutico para el tratamiento del cáncer
Bayley et al. Photoactivatable drugs
He et al. Toxicities and therapeutic effect of 5-fluorouracil controlled release implant on tumor-bearing rats
AU760619B2 (en) Synergism of photodynamic and electropermeation effects on cell vitality as a novel cytotoxic agent
IL121272A0 (en) Nucleotide comprising compositions and their use for improving therapeutic index of a therapeutic drug
Říhová et al. Targetable photoactivalable drugs. 3. In vitro efficacy of polymer bound chlorin e6 toward human hepatocarcinoma cell line (PLC/PRF/5) targeted with galactosamine and to mouse splenocytes targeted with anti-Thy 1.2 antibodies
CA2194485A1 (en) Endothelial lining effects and treatment of vasospastic disorders

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties